Enclomiphene

—

evidence score

hormonal

Prescription Only

enclomiphene citratetrans-clomipheneAndroxal+1 more

Enclomiphene is the trans-isomer of clomiphene citrate (clomid), isolated from the racemic mixture to provide the active estrogen-antagonist component without the estrogenic zuclomiphene (cis-) isomer. It is a selective estrogen receptor modulator (SERM) that blocks estrogen negative feedback at the hypothalamus and pituitary, resulting in increased LH and FSH secretion — which stimulates the testes to produce testosterone. Unlike exogenous testosterone, it maintains the entire HPG axis and preserves fertility (sperm production continues). Phase III trials in secondary hypogonadism showed testosterone normalization while preserving semen parameters. Often favored over TRT by younger men and those planning families.

Evidence

No score yet

Safety

Unknown safety profile

Clinical Status

No formal phase listed

Research Sync

Not synced yet

Dosing

Typical

25 mg

12.5 mgRange50 mg

Frequencydaily

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~5-7 days

OnsetLH/FSH increase within days; testosterone normalization 4-8 weeks

DurationTestosterone elevation maintained during use; returns toward baseline 4-8 weeks after stopping

Routes

oral

Evidence Score

—

0 studies indexed

Scoring Factors

Volume(40%)—

Quality(30%)—

Sample Size(10%)—

Consistency(10%)—

Replication(5%)—

Recency(5%)—

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

Enclomiphene is currently categorized as a hormonal compound.

Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

Blocks ER-alpha in hypothalamus and pituitary, reducing estrogen negative feedback; pulsatile GnRH/LH/FSH increase drives testicular testosterone production and spermatogenesis

Practical Context

Strongest current signals

No indexed study summaries yet.